Impact of fludrocortisone on the outcomes of subarachnoid hemorrhage patients: A retrospective analysis.
J Stroke Cerebrovasc Dis
; 33(6): 107643, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38387759
ABSTRACT
BACKGROUND:
Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH).METHODS:
We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. The primary outcome was adjusted for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were neurologic and cardiopulmonary dysfunction events.RESULTS:
Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64 % were female, and 41 (53 %) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95 % CI, 0.14-0.80; P = 0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different delayed cerebral ischemia (22 % vs. 39 %, P = 0.16); cardiac dysfunction (0 % vs. 11 %; P = 0.10); and pulmonary edema (15 % vs. 8 %; P = 0.59).CONCLUSIONS:
The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hemorragia Subaracnóidea
/
Fludrocortisona
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article